<p>Woodline Partners LP 在最近向證券交易委員會提交的 13F 表格中表示，在第四季度將其在 KalVista Pharmaceuticals, Inc.（NASDAQ:KALV - 免費報告）股票中的持倉增加了 111.8%。該公司在此期間額外購買了 680,148 股後，持有該專業製藥公司 1,288,401 股股票。到最近一個季度末，Woodline Partners LP 持有的 KalVista Pharmaceuticals 股票約佔 2.61%，價值 10,913,000 美元。</p>
<p>其他機構投資者和對沖基金最近也增加或減少了在該公司的股份。SG Americas Securities LLC 在第四季度將其在 KalVista Pharmaceuticals 的持倉提高了 10.0%。SG Americas Securities LLC 目前持有 14,508 股該專業製藥公司的股票，價值 123,000 美元，此前在此期間額外購買了 1,319 股。Tower Research Capital LLC TRC 在第四季度將其在 KalVista Pharmaceuticals 的股份提高了 666.9%。Tower Research Capital LLC TRC 目前持有 6,327 股該專業製藥公司的股票，價值 54,000 美元，此前在上個季度購買了 5,502 股。Dimensional Fund Advisors LP 在第四季度將其在 KalVista Pharmaceuticals 的持倉提高了 14.7%。Dimensional Fund Advisors LP 目前持有 696,037 股該專業製藥公司的股票，價值 5,895,000 美元，此前在此期間額外購買了 89,001 股。Wellington Management Group LLP 在第四季度將其在 KalVista Pharmaceuticals 的股份提高了 4.2%。Wellington Management Group LLP 目前持有 122,863 股該專業製藥公司的股票，價值 1,041,000 美元，此前在上個季度購買了 4,940 股。最後，Wells Fargo &amp; Company MN 在第四季度將其在 KalVista Pharmaceuticals 的股份提高了 29.1%。Wells Fargo &amp; Company MN 目前持有 20,165 股該專業製藥公司的股票，價值 171,000 美元，此前在上個季度購買了 4,543 股。</p>
<h2>KalVista Pharmaceuticals 的內部買賣</h2>
<p>在其他消息中，內部人士 Paul K. Audhya 於 5 月 19 日星期一出售了 2,776 股該股票。股票以平均價格 11.84 美元出售，總交易額為 32,867.84 美元。出售後，內部人士現在持有該公司 106,611 股股票，價值約 1,262,274.24 美元。這代表其持股比例減少了 2.54%。該出售在向證券交易委員會提交的文件中披露，可以通過此鏈接訪問。此外，首席執行官 Benjamin L. Palleiko 於 5 月 19 日星期一出售了 3,808 股 KalVista Pharmaceuticals 股票。股票以平均價格 11.84 美元出售，總價值為 45,086.72 美元。交易完成後，首席執行官現在直接持有 293,367 股該公司的股票，價值 3,473,465.28 美元。這代表其持股比例減少了 1.28%。該出售的披露信息可以在這裏找到。內部人士在過去九十天內共出售了價值 181,770 美元的 15,647 股公司股票。公司內部人士持有該公司 10.50% 的股票。</p>
<h2>KalVista Pharmaceuticals 股票表現</h2>
<p>KALV 在星期五開盤價為 11.42 美元。KalVista Pharmaceuticals, Inc. 的 12 個月低點為 7.30 美元，12 個月高點為 15.50 美元。該公司的市值為 5.6776 億美元，市盈率為 -3.14，貝塔值為 0.05。該公司的 50 日簡單移動平均線為 11.97 美元，200 日簡單移動平均線為 10.45 美元。</p>
<h2>分析師評級變動</h2>
<p>一些股票分析師最近對 KALV 股票發佈了報告。JMP Securities 在 1 月 31 日星期五的研究報告中啓動了對 KalVista Pharmaceuticals 股票的覆蓋。他們給予該公司 &#34;跑贏大盤&#34; 的評級，目標價為 19.00 美元。Jones Trading 在 3 月 26 日星期三的研究報告中重申了 &#34;買入&#34; 評級，並給予 KalVista Pharmaceuticals 股票 30.00 美元的目標價。Needham &amp; Company LLC 在 4 月 8 日星期二的研究報告中重申了 &#34;買入&#34; 評級，並設定了 28.00 美元的目標價。HC Wainwright 在 3 月 14 日星期五的報告中重申了 &#34;買入&#34; 評級，並設定了 20.00 美元的目標價。最後，Citizens Jmp 在 1 月 31 日星期五的研究報告中將 KalVista Pharmaceuticals 的評級上調至 &#34;強力買入&#34;。七位股票研究分析師對該股票給予了買入評級，一位分析師給予了該公司股票強力買入評級。根據 MarketBeat.com，該公司目前的平均評級為 &#34;買入&#34;，平均目標價為 24.83 美元。</p>
<p><strong>查看我們對 KALV 的最新分析</strong></p>
<h2>關於 KalVista Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>KalVista Pharmaceuticals, Inc. 是一家臨牀階段的製藥公司，專注於發現、開發和商業化針對未滿足需求疾病的藥物療法抑制劑。該公司的產品候選藥物是 Sebetralstat，一種小分子血漿激肽酶抑制劑，針對遺傳性血管性水腫（HAE）疾病。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票比 KalVista Pharmaceuticals 更好</li>
<li>股票評級和建議：理解分析師評級</li>
<li>Joby 股票的動盪：近期下跌的原因是什麼？</li>
<li>最具波動性的股票，投資者需要知道的事項</li>
<li>為什麼嘉年華可能是終極非科技增長股票</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>超級微型計算機股票在沙特訂單中開闢新路徑</li>
</ul>
<p><strong>想看看其他對沖基金持有 KALV 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 KalVista Pharmaceuticals, Inc.（NASDAQ:KALV - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 KalVista 製藥嗎？</h2>
<p>在考慮 KalVista 製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 KalVista 製藥並不在名單上。</p>
<p>雖然 KalVista 製藥目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

KalVista制藥

<p>Woodline Partners LP 在第四季度將其在 KalVista Pharmaceuticals 的持股增加了 111.8%，收購了 680,148 股，使其總持股達到 1,288,401 股，價值 1,090 萬美元。其他機構投資者也調整了他們的持倉。內部人士進行了股票出售，首席執行官 Benjamin L. Palleiko 和內部人士 Paul K. Audhya 出售了股份。KalVista 的股票開盤價為 11.42 美元，市值為 5.6776 億美元。分析師們給予了積極的評級，平均目標價為 24.83 美元</p>

<p>Woodline Partners LP boosted its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 111.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 1,288,401 shares of the specialty pharmaceutical company's stock after acquiring an additional 680,148 shares during the period. Woodline Partners LP owned approximately 2.61% of KalVista Pharmaceuticals worth $10,913,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Woodline Partners LP 在最近向證券交易委員會提交的 13F 表格中表示，在第四季度將其在 KalVista Pharmaceuticals, Inc.（NASDAQ:KALV - 免費報告）股票中的持倉增加了 111.8%。該公司在此期間額外購買了 680,148 股後，持有該專業製藥公司 1,288,401 股股票。到最近一個季度末，Woodline Partners LP 持有的 KalVista Pharmaceuticals 股票約佔 2.61%，價值 10,913,000 美元。</p>
</div><p>Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its position in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after acquiring an additional 1,319 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after purchasing an additional 5,502 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in KalVista Pharmaceuticals by 14.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 696,037 shares of the specialty pharmaceutical company's stock worth $5,895,000 after purchasing an additional 89,001 shares during the period. Wellington Management Group LLP boosted its stake in KalVista Pharmaceuticals by 4.2% during the fourth quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company's stock worth $1,041,000 after buying an additional 4,940 shares in the last quarter. Finally, Wells Fargo &amp; Company MN boosted its stake in KalVista Pharmaceuticals by 29.1% during the fourth quarter. Wells Fargo &amp; Company MN now owns 20,165 shares of the specialty pharmaceutical company's stock worth $171,000 after buying an additional 4,543 shares in the last quarter.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也增加或減少了在該公司的股份。SG Americas Securities LLC 在第四季度將其在 KalVista Pharmaceuticals 的持倉提高了 10.0%。SG Americas Securities LLC 目前持有 14,508 股該專業製藥公司的股票，價值 123,000 美元，此前在此期間額外購買了 1,319 股。Tower Research Capital LLC TRC 在第四季度將其在 KalVista Pharmaceuticals 的股份提高了 666.9%。Tower Research Capital LLC TRC 目前持有 6,327 股該專業製藥公司的股票，價值 54,000 美元，此前在上個季度購買了 5,502 股。Dimensional Fund Advisors LP 在第四季度將其在 KalVista Pharmaceuticals 的持倉提高了 14.7%。Dimensional Fund Advisors LP 目前持有 696,037 股該專業製藥公司的股票，價值 5,895,000 美元，此前在此期間額外購買了 89,001 股。Wellington Management Group LLP 在第四季度將其在 KalVista Pharmaceuticals 的股份提高了 4.2%。Wellington Management Group LLP 目前持有 122,863 股該專業製藥公司的股票，價值 1,041,000 美元，此前在上個季度購買了 4,940 股。最後，Wells Fargo &amp; Company MN 在第四季度將其在 KalVista Pharmaceuticals 的股份提高了 29.1%。Wells Fargo &amp; Company MN 目前持有 20,165 股該專業製藥公司的股票，價值 171,000 美元，此前在上個季度購買了 4,543 股。</p>
</div><h2>Insider Buying and Selling at KalVista Pharmaceuticals</h2>
<div class="lb-trans"><h2>KalVista Pharmaceuticals 的內部買賣</h2>
</div><p>In other news, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the sale, the insider now owns 106,611 shares in the company, valued at approximately $1,262,274.24. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 3,808 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $45,086.72. Following the completion of the transaction, the chief executive officer now directly owns 293,367 shares of the company's stock, valued at $3,473,465.28. This represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,647 shares of company stock worth $181,770 over the last ninety days. Corporate insiders own 10.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，內部人士 Paul K. Audhya 於 5 月 19 日星期一出售了 2,776 股該股票。股票以平均價格 11.84 美元出售，總交易額為 32,867.84 美元。出售後，內部人士現在持有該公司 106,611 股股票，價值約 1,262,274.24 美元。這代表其持股比例減少了 2.54%。該出售在向證券交易委員會提交的文件中披露，可以通過此鏈接訪問。此外，首席執行官 Benjamin L. Palleiko 於 5 月 19 日星期一出售了 3,808 股 KalVista Pharmaceuticals 股票。股票以平均價格 11.84 美元出售，總價值為 45,086.72 美元。交易完成後，首席執行官現在直接持有 293,367 股該公司的股票，價值 3,473,465.28 美元。這代表其持股比例減少了 1.28%。該出售的披露信息可以在這裏找到。內部人士在過去九十天內共出售了價值 181,770 美元的 15,647 股公司股票。公司內部人士持有該公司 10.50% 的股票。</p>
</div><h2>KalVista Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>KalVista Pharmaceuticals 股票表現</h2>
</div><p>KALV opened at $11.42 on Friday. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The firm has a market cap of $567.76 million, a price-to-earnings ratio of -3.14 and a beta of 0.05. The firm's 50-day simple moving average is $11.97 and its 200-day simple moving average is $10.45.</p>
<div class="lb-trans"><p>KALV 在星期五開盤價為 11.42 美元。KalVista Pharmaceuticals, Inc. 的 12 個月低點為 7.30 美元，12 個月高點為 15.50 美元。該公司的市值為 5.6776 億美元，市盈率為 -3.14，貝塔值為 0.05。該公司的 50 日簡單移動平均線為 11.97 美元，200 日簡單移動平均線為 10.45 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of equities analysts have recently issued reports on KALV shares. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an &#34;outperform&#34; rating and a $19.00 price objective for the company. Jones Trading reissued a &#34;buy&#34; rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, Citizens Jmp upgraded KalVista Pharmaceuticals to a &#34;strong-buy&#34; rating in a research note on Friday, January 31st. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of &#34;Buy&#34; and an average price target of $24.83.</p>
<div class="lb-trans"><p>一些股票分析師最近對 KALV 股票發佈了報告。JMP Securities 在 1 月 31 日星期五的研究報告中啓動了對 KalVista Pharmaceuticals 股票的覆蓋。他們給予該公司 &#34;跑贏大盤&#34; 的評級，目標價為 19.00 美元。Jones Trading 在 3 月 26 日星期三的研究報告中重申了 &#34;買入&#34; 評級，並給予 KalVista Pharmaceuticals 股票 30.00 美元的目標價。Needham &amp; Company LLC 在 4 月 8 日星期二的研究報告中重申了 &#34;買入&#34; 評級，並設定了 28.00 美元的目標價。HC Wainwright 在 3 月 14 日星期五的報告中重申了 &#34;買入&#34; 評級，並設定了 20.00 美元的目標價。最後，Citizens Jmp 在 1 月 31 日星期五的研究報告中將 KalVista Pharmaceuticals 的評級上調至 &#34;強力買入&#34;。七位股票研究分析師對該股票給予了買入評級，一位分析師給予了該公司股票強力買入評級。根據 MarketBeat.com，該公司目前的平均評級為 &#34;買入&#34;，平均目標價為 24.83 美元。</p>
</div><p><strong>View Our Latest Analysis on KALV</strong></p>
<div class="lb-trans"><p><strong>查看我們對 KALV 的最新分析</strong></p>
</div><h2>About KalVista Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 KalVista Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).</p>
<div class="lb-trans"><p>KalVista Pharmaceuticals, Inc. 是一家臨牀階段的製藥公司，專注於發現、開發和商業化針對未滿足需求疾病的藥物療法抑制劑。該公司的產品候選藥物是 Sebetralstat，一種小分子血漿激肽酶抑制劑，針對遺傳性血管性水腫（HAE）疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than KalVista Pharmaceuticals</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Super Micro Computer Stock Clears New Path Higher on Saudi Orders</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 KalVista Pharmaceuticals 更好</li>
<li>股票評級和建議：理解分析師評級</li>
<li>Joby 股票的動盪：近期下跌的原因是什麼？</li>
<li>最具波動性的股票，投資者需要知道的事項</li>
<li>為什麼嘉年華可能是終極非科技增長股票</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>超級微型計算機股票在沙特訂單中開闢新路徑</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding KALV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有 KALV 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 KalVista Pharmaceuticals, Inc.（NASDAQ:KALV - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=KALV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in KalVista Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 KalVista 製藥嗎？</h2>
</div><p>Before you consider KalVista Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 KalVista 製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 KalVista 製藥並不在名單上。</p>
</div><p>While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 KalVista 製藥目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Woodline Partners LP 購入了 680,148 股 KalVista 製藥公司（NASDAQ:KALV）的股票